Publications Prof. Dr. Kristian Reich |
Original work
1. Dirschka T, Reich K, Bissonnette R, Maares J, Brown T, Diepgen TL. An
open-label study assessing the safety and efficacy of alitretinoin in
patients with severe chronic hand eczema unresponsive to topical
corticosteroids. Clin Exp Dermatol. 2010 Nov 10. [Epub in Medline ahead
of print]
2. Franzke N, Schäfer I, Jost K, Blome C, Rustenbach
SJ, Reich K, Reusch M, Maurer M, Augustin M. A new instrument for the
assessment of patient-defined benefit in the treatment of allergic
rhinitis. Allergy. 2010 Dec 1. [Epub in Medline ahead of print]
3.
Kasperkiewicz M, Schmidt E, Frambach Y, Rose C, Meier M, Nitschke M,
Falk TM, Reich K, Ludwig RJ, Zillikens D. Improvement of
treatment-refractory atopic dermatitis by immunoadsorption: A pilot
study. J Allergy Clin Immunol. 2011;127(1):267-70.
4. Mrowietz U,
Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou
C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P,
Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach
T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition
of treatment
goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 201 ;303(1):1-10.
5.
Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K,
Kupper H, Goldblum O, Thaçi D. Efficacy and safety of adalimumab in
patients with psoriasis previously treated with anti-tumour necrosis
factor agents: subanalysisof BELIEVE. J Eur Acad Dermatol Venereol. 2011
Jan 9. [Epub in Medline ahead of print]
6, Radtke MA,
Langenbruch AK, Schäfer I, Herberger K, Reich K, Augustin M. Nail
psoriasis as a severity indicator: results from the PsoReal study.
Patient Related Outcome Measures. 2011;2:1-6.
7. Reich K,
Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, Guenther
L,Langley RG. Ustekinumab decreases work limitations, improves work
productivity,and reduces work days missed in patients with
moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog
Treat. 2010 Oct 31. [Epub in Medline ahead of print]
8. Augustin
M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I.
Epidemiology and comorbidity of psoriasis in children. Br J Dermatol.
2010;162(3):633-6.
9. Augustin M, Reich K, Blome C, Schäfer I,
Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden
of disease. Br J Dermatol. 2010;163(3):580-5.
10. Augustin M,
Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related
prevalence of psoriasis: Analysis of health insurance data in Germany.
Acta Derm Venereol. 2010;90(2):147-51.
11. Avouac J, Walker U,
Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y; EUSTAR, Miniati I,
Muller A, Iannone F, Distler O, Becvar R, Sierakowsky S, Kowal-Bielecka
O, Coelho P, Cabane J, Cutolo M, Shoenfeld Y, Valentini G, Rovensky J,
Riemekasten G, Vlachoyiannopoulos P, Caporali R, Jiri S, Inanc
M,Zimmermann Gorska I, Carreira P, Novak S, Czirjak L, Oliveira Ramos F,
Jendro M, Chizzolini C, Kucharz EJ, Richter J, Cozzi F, Rozman B,
Mallia CM, Gabrielli A,Farge D, Kiener HP, Schöffel D, Airo P, Wollheim
F, Martinovic D, Trotta F, Jablonska S, Reich K, et al. Characteristics
of joint involvement and relationships with systemic inflammation in
systemic sclerosis: results from the EULAR Scleroderma Trial and
Research Group (EUSTAR) database. J Rheumatol. 2010;37(7):1488-501.
12.
Hüffmeier U, Bergboer JG, Becker T, Armour JA, Traupe H, Estivill X,
Riveira-Munoz E, Mössner R, Reich K, Kurrat W, Wienker TF, Schalkwijk J,
Zeeuwen PL, Reis A. Replication of LCE3C-LCE3B CNV as a risk factor for
psoriasis and analysis of interaction with other genetic risk factors. J
Invest Dermatol. 2010;130(4):979-84.
13. Kingo K, Mössner R,
Traks T, Rätsep R, Raud K, Reimann E, Krüger U, Silm H, Vasar E, Reich
K, Kõks S. Further association analysis of chr 6q22-24 suggests a role
of IL-20RA polymorphisms in psoriasis. J Dermatol Sci. 2010;57(1):71-3.
14.
Lebwohl M, Yeilding N, Szapary P, Wang Y, Li S, Zhu Y, Reich K, Langley
RG, Papp KA. Impact of weight on the efficacy and safety of ustekinumab
in patients with moderate to severe psoriasis: Rationale for dosing
recommendations. J Am Acad Dermatol. 2010;63(4):571-9.
15. Radtke
MA, Augustin J, Blome, C, Reich K, Rustenbach SJ, Schäfer I, Laass A,
Augustin M. How do regional factors influence psoriasis patient care in
Germany? J Deutsch Ges Dermatol. 2010;8(7):516-24.
16. Reich K,
Ortonne JP, Kerkmann U, Wang Y, Saurat JH, Papp K, Langley R, Griffiths
CE. Skin and Nail Responses after 1 Year of Infliximab Therapy in
Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of
the EXPRESS Trial. Dermatology. 2010;221(2):172-8.
17. Reich K,
Shakery K, Mrowietz U, Szapary PO, Wang Y, Hsu M-C, Langley RG.
Ustekinumab and marked clinical responses in patients with moderate to
severe psoriasis. Psoriasis Forum. 2010;16(1):3-11.
18. Reich K,
Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani
PM. Benefit-risk analysis of adalimumab versus methotrexate and placebo
in the treatment of moderate to severe psoriasis: comparison of adverse
event-free response days in the CHAMPION trial. J Am Acad Dermatol.
2010;63(6):1011-8.
19. Szeimies RM, Radny P, Sebastian M,
Borrosch F, Dirschka T, Krähn-Senftleben G, Reich K, Pabst G, Voss D,
Foguet M, Gahlmann R, Lübbert H, Reinhold U. Photodynamic therapy with
BF-200 ALA for the treatment of actinic keratosis: results of a
prospective, randomized, double-blind, placebo-controlled phase III
study. Br J Dermatol. 2010;163(2):386-94.
20. Szeimies RM,
Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H,
Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M,
Hauschild A. Long-term follow-up of photodynamic therapy with a
self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J
Dermatol. 2010;162(2):410-4.
21. Augustin M, Reich K, Reusch M, Luger T, Franzke N, Schäfer I, Rustenbach SJ, Radtke MA. Health Services Research in Psoriasis - The German Approach. Dermatology. 2009 Mar 6. [Epub ahead of print]
22.
Hüffmeier U, Lascorz J, Böhm B, Lohmann J, Wendler J, Mössner R, Reich
K, Traupe H, Kurrat W, Burkhardt H, Reis A. Genetic variants of the
IL-23R pathway: association with psoriatic arthritis and psoriasis
vulgaris, but no specific risk factor for arthritis. J Invest Dermatol.
2009; 129(2): 355-8.
23. Mease PJ, Reich K.
Alefacept with methotrexate for treatment of psoriatic arthritis:
open-label extension of a randomized, double-blind, placebo controlled
study. J Am Acad Dermatol. 2009; 60(3): 402-11
24. Mössner R, Stiens G, König IR, Schmidt D, Platzer A, Krüger U,
Reich K.
Analysis of a functional serotonin transporter promoter polymorphism in
psoriasis vulgaris. Arch Dermatol Res. 2009; 301(6): 443-7.
25.
Müller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz
U, Ochsenkühn T, Radke M, Reich K, Rudwaleit M, Schreiber S. ["TRECID",
TNF alpha related chronic inflammatory diseases - a new multiple
diseases bridging concept. Dtsch Med Wochenschr.2009; 134(42): 2132-6
26. Radtke MA, Reich K, Blome C, Kopp I, Rustenbach SJ, Schäfer I, Augustin M. Evaluation of Quality of Care and Guideline-Compliant Treatment in Psoriasis. Development of a New System of Quality Indicators. Dermatology. 2009; 219(1): 54-8.
27. Radtke M, Reich K, Blome C, Rustenbach S, Augustin M. Prevalence
and clinical features of psoriatic arthritis and joint complaints in
2009 patients with psoriasis: results of a German national survey. J Eur
Acad Dermatol Venereol.
2009; 23(6): 683-91.
28. Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Szeimies RM. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies.Br J Dermatol. 2009;160(5):1066-74.
29. Hüffmeier U, Lascorz J, Böhm B, Lohmann J, Wendler J, Mössner R, Reich K, Traupe H, Kurrat W, Burkhardt H, Reis A. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol. 2009;129(2):355-8.
30. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040-7.
31. Reich K. Wirksamkeit und Sicherheit des humanen monoklonalen Interleukin-12/23-Antikörpers Ustekinumab bei Patienten mit Psoriasis: Ergebnisse der randomisierten, doppel-blinden, plazebokontrollierten Phase-III-Studien PHOENIX 1 und PHOENIX 2. Akt Dermatol. 2009;35(1/2):29-34.
32. Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2009;60(3):402-11.
33. van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K, Saari S, Segaert S, Vaillant L. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol. 2009 Jan;160(1):170-6.
34. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008;216(4):366-72.
35. Augustin M, Reich K, Reich C, Purwins S, Jeff Rustenbach S, Schäfer I, Radtke M. Quality of psoriasis care in Germany - results of the national study PsoHealth 2007. J Dtsch Dermatol Ges. 2008;6(8):640-5.
36. Chang YM, Newton-Bishop JA, Bishop DT, Armstrong BK, Bataille V, Bergman W, Berwick M, Bracci PM, Elwood JM, Ernstoff MS, Green AC, Gruis NA, Holly EA, Ingvar C, Kanetsky PA, Karagas MR, Marchand LL, Mackie RM, Olsson H, Osterlind A, Rebbeck TR, Reich K, Sasieni P, Siskind V, Swerdlow AJ, Titus-Ernstoff L, Zens MS, Ziegler A, Barrett JH. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer. 2008;124(2):420-8.
37. Haenssle H, Buhl T, Knudsen S, Krueger U, Rosenberger A, Reich K, Neumann C. CD40 ligation during dendritic cell maturation reduces cell death and prevents interleukin-10-induced regression to macrophage-like monocytes. Exp Dermatol. 2008;17(3):177-87.
38. Kingo K, Mössner R, Rätsep R, Raud K, Krüger U, Silm H, Vasar E, Reich K, Kõks S. Association analysis of IL20RA and IL20RB genes in psoriasis. Genes Immun. 2008;9(5):445-51.
39. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008 ;371(9625): 1675-84.
40. Reich K, Griffiths C, Barker J, Chimenti S, Daudén E, Gianetti A, Gniadecki R, Katsambas A, Langley R, Mrowietz U, Ogilvie A, Ortonne JP, Reider N, Saurat JH. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology. 2008;217(3):268-75.
41. Rich P, Griffiths CEM, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008;58(2):224-31.
42. Zschocke I, Reich C, Zielke A, Reitmeier N, Reich K. Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: results of a randomized, open-label trial. J Dermatolog Treat. 2008;19(3):176-81.
43. Kingo K, Mössner R, Kõks S, Rätsep R, Krüger U, Vasar E, Reich K, Silm H. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol. 2007;156(4):646-52.
44. Mössner R, Anders N, König IR, Krüger U, Schmidt D, Berking C, Ziegler A, Brockmöller J, Kaiser R, Volkenandt M, Westphal GA, Reich K. Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Arch Dermatol Res. 2007;298(8):371-9.
45. Mössner R, Meyer P, Jankowski F, König IR, Kruger U, Kammerer S, Westphal G, Boettger MB, Berking C, Schmitt C, Brockmöller J, Ziegler A, Stapelmann H, Kaiser R, Volkenandt M, Reich K. Vatiations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk. Cancer Lett. 2007;246(1-2):218-23.
46. Niedermeier A, Eming R, Pfütze M, Neumann CR, Happel C, Reich K, Hertl M. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol. 2007;143(2):192-8.
47. Reich K, Huffmeier U, König IR, Lascorz J, Lohmann J, Wendler J, Traupe H, Mössner R, Reis A, Burkhardt H. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum. 2007;56(6):2056-2064.
48. Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol. 2007;17(5):381-6.
49. Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, Reich K. Krankheitskosten und Lebensqualität bei Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris in Deutschland: eine multizentrische Studie. J Dtsch Dermatol Ges. 2007;5(3):209-19.
50. Huffmeier U, Steffens M, Burkhardt H, Lascorz J, Schurmeier-Horst F, Stander M, Kelsch R, Baumann C, Kuster W, Mössner R, Reich K, Wienker TF, Traupe H, Reis A. Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients. J Med Genet. 2006;43(6):517-22.
51. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo CA, Li S, Dooley LT, Griffiths CE. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate- to-severe psoriasis: a randomized controlled trial. Brit J Dermatol. 2006;154(6):1161-8.
52. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M. Cost of moderate-to-severe plaque-psoriasis in Germany: a multicentre cost-of-illness study. Dermatology. 2006;212(2):137-44.
53. Blankenburg S, König IR, Mössner R, Laspe P, Thoms KM, Krüger U, Khan SG, Westphal G, Berking C, Volkenandt M, Reich K, Neumann C, Ziegler A, Kraemer KH, Emmert S. Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study. Carcinogenesis. 2005;26(6):1085-90.
54. Blankenburg S, König IR, Mössner R, Laspe P, Thoms KM, Krüger U, Khan SG, Westphal G, Volkenandt M, Neumann C, Ziegler A, Kraemer KH, Reich K, Emmert S. No association between three xeroderma pigmentosum group C and one group G gene polymorphisms and risk of cutaneous melanoma. Eur J Hum Genet. 2005;13(2):253-5.
55. Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, Matucci-Cerinic M, Chilla M, Reich K, Kalden JR, Muller-Ladner U, Lorenz HM, Gay S, Distler O. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 2005;52(3):856-64.
56. Mössner R, Kingo K, Kleensang A, Krüger U, König IR, Silm H, Westphal GA, Reich K. Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol. 2005;124(1):282-4.
57. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367-74.
58. Mössner R, Beckmann I, Hallermann C, Neumann C, Reich K. Granulocyte colony-stimulating-factor-induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation. Exp Dermatol. 2004;13(6):340-6.
59. Mössner R, Kaiser R, Matern P, Kruger U, Westphal GA, Brockmöller J, Ziegler A, Neumann C, König IR, Reich K. Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis. Arch Dermatol Res. 2004;296(1):1-5.
60. Mössner R, Tings T, Beckmann I, Neumann C, Paulus W, Reich K. A close look at autoimmune muscle disorders: association of Lambert-Eaton myasthenic syndrome with dermatomyositis. Scand J Rheumatol. 2004;33(4):271-5.
61. Reich K, Hugo S, Middel P, Blaschke V, Heine A, Neumann C. The maturation-dependent production of interleukin-16 is impaired in monocyte-derived dendritic cells from atopic dermatitis patients but is restored by inflammatory cytokines TNF-alpha and IL-1beta. Exp Dermatol. 2004;13(12):740-7.
62. Blaschke S, Middel P, Dorner BG, Blaschke V, Hummel KM, Kroczek RA, Reich K, Benoehr P, Koziolek M, Muller GA. Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis. Arthritis Rheum. 2003;48(7):1858-72.
63. Reich K, Westphal GA, König IR, Mössner R, Krüger U, Ziegler A, Neumann C, Schnuch A. Association of allergic contact dermatitis with a promoter polymorphism in the IL16 gene. J Allergy Clin Immunol. 2003;112(6):1191-4.
64. Reich K, Westphal GA, König IR, Mössner R, Schupp P, Gutgesell C, Hallier E, Ziegler A, Neumann Ch. Cytokine gene polymorphisms in atopic dermatitis. Br J Dermatol. 2003;148(6):1237-41.
65. Westphal GA, Schnuch A, Mössner R, König IR, Kränke B, Hallier E, Ziegler A, Reich K. Cytokine gene polymorphisms in allergic contact dermatitis. Contact Dermatitis. 2003;48(2):93-8.
66. Blaschke V, Reich K, Blaschke S, Zipprich S, Neumann C. Quantitative RT-PCR: comparing real-time lightcycler technology with quantitative competitive RT-PCR. Biochemica. 2002;(1):6-8.
67. Mössner R, Schulz U, Krüger U, Middel P, Schinner S, László Fuzesi L, Neumann C, Reich K. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol. 2002;119(3):576-82.
68. Reich K, Hugo S, Middel P, Blaschke V, Heine A, Gutgesell C, Williams R, Neumann Ch. Evidence for a role of Langerhans cell-derived interleukin-16 in atopic dermatitis. J Allergy Clin Immunol. 2002;109(4):681-7.
69. Reich K, Mössner R, König IR, Westphal G, Ziegler A, Neumann Ch. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol. 2002;118(1):155-63.
70. Middel P, Reich K, Polzien F, Blaschke V, Hemmerlein B, Herms J, Korabiowska M, Radzun HJ. Interleukin-16 expression and phenotype of interleukin-16 producing cells in Crohn's disease. Gut. 2001;49(6):795-803.
71. Middel P, Thelen P, Blaschke S, Polzien F, Reich K, Blaschke V, Wrede A, Hummel KM, Gunawan B, Radzun HJ. Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's disease. Am J Pathol. 2001;159(5):1751-61.
72. Reich K, Garbe C, Blaschke V, Maurer C, Middel P, Westphal G, Lippert U, Neumann Ch. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal IL-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol. 2001;116(2):319-29.
73. Reich K, Heine A, Hugo S, Blaschke V, Middel P, Kaser A, Tilg H, Blaschke S, Gutgesell C, Neumann Ch. Engagement of the high affinity IgE receptor, FceRI, stimulates the production of IL-16 in Langerhans cell-like dendritic cells. J Immunol. 2001;167(11):6321-9.
74. Blaschke V, Reich K, Blaschke S, Zipprich S, Neumann Ch. Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells, Validation of a new real-time RT-PCR technology. J Immunol Methods. 2000;246(1-2):79-90.
75. Westphal GA, Reich K, Schulz TG, Neumann Ch, Hallier E, Schnuch A. N-acetyltransferases 1 and 2 polymorphisms in para-substituted arylamine-induced contact allergy. Br J Dermatol. 2000;142(6):1121-7.
76. Westphal GA, Schnuch A, Schulz TG, Reich K, Aberer W, Brasch J, Koch P, Wessbecher R, Szliska C, Bauer A, Hallier E. Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization. Int Arch Occup Environ Health. 2000;73(6):384-8.
77. Blaschke V, Reich K, Middel P, Letschert M, Sachse F, Harwix S, Neumann Ch. Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides. J Invest Dermatol. 1999;113(4):658-63.
78. Reich K, Brinck U, Letschert M, Blaschke V, Dames K, Braess J, Wörmann B, Rünger TM, Neumann Ch. Graft-versus-host disease-like cutaneous immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Br J Dermatol. 1999;141(4):739-46 .
79. Reich K, Westphal GA, Schulz TG, Müller M, Zipprich S, Fuchs Th, Hallier E, Neumann Ch. Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. J Invest Dermatol. 1999;113(2):214-20.
80. Vente C, Reich K, Rupprecht R, Neumann Ch. Erosive mucosal lichen planus, response to topical treatment with tacrolimus. Br J Dermatol. 1999;140(2):338-42.
81. Reich K, Brück M, Gräfe A, Vente C, Neumann Ch, Garbe C. Treatment of psoriasis with interleukin-10. J Invest Dermatol. 1998;111(6):1235-6. [letter]
82. Schnuch A, Westphal GA, Müller MM, Schulz TG, Geier J, Brasch J, Merk HF, Kawakubo Y, Richter G, Koch P, Fuchs Th, Gutgesell C, Reich K, Gebhardt M, Becker D, Grabbe J, Sziska C, Aberer W, Hallier E. Genotype and phenotype of N-acetyltransferase 2 (NAT2): polymorphism in patients with contact allergy. Contact Dermatitis. 1998;38(4):209-11.
83. Boxberger HJ, Meyer TF, Grausam MC, Reich K, Becker HD, Sessler MJ. Isolating and maintaining highly polarized primary epithelial cells from normal human duodenum for growth as spheroid-like vesicles. In Vitro Cell Dev Biol Anim. 1997;35(7):536-45.
84. Braess J, Reich K, Willert S, Strutz F, Neumann Ch, Hiddemann W, Wörmann B. Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin´s lymphoma of B-cell type (B-NHL). Ann Hematol. 1997;75(5-6):227-30.
85. Seifarth C, Deusch K, Reich K, Classen M. Local cellular immune response in Helicobacter pylori associated type B-gastritis - selective increase of CD4+ but not gamma/delta T-cells in the immune response to H. pylori antigens. Z Gastroenterol. 1996;34(4):215-24.
86. Reich K, Dähne I, Endres N, Classen M, Deusch K. Biased T-cell receptor V-beta repertoire of intestinal CD8+ T-cells in HIV-disease. Adv Exp Med Biol. 1995;371B:1023-6.
87. Seifarth C, Funk A, Reich K, Dähne I, Classen M, Deusch K. Selective increase of CD4+ and CD25+ T-cells but not of gamma/delta T-cells in H pylori associated gastritis. Adv Exp Med Biol. 1995;371B:931-4.
88. Van-Kerckhove C, Russel GJ, Deusch K, Reich K, Bhan AK, DerSimonian H, Brenner MB. Oligoclonality of human intestinal intraepithelial T-cells. J Exp Med. 1992;175(1):57-63.
89. Deusch K, Lüling F, Reich K, Classen M, Wagner H, Pfeffer K. A major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma/delta T-cell receptor, the CD8 accessory molecule and preferentially uses the V-delta 1 gene segment. Eur J Immunol. 1991;21(4):1053-9.
90. Deusch K, Pfeffer K, Reich K, Gstettenbauer M, Daum S, Lüling F, Classen M. Phenotypic and functional characterization of human TCR gamma/delta+ intestinal intraepithelial lymphocytes. Curr Top Microbiol Immunol. 1991;173:279-83.